ImmunoVaccine Inc. (TSE:IMV) has been given a C$2.50 price target by analysts at National Bank Financial in a research report issued on Wednesday. The firm presently has an “outperform” rating on the stock. National Bank Financial’s target price points to a potential upside of 104.92% from the company’s previous close.
ImmunoVaccine (TSE:IMV) traded down 0.82% on Wednesday, reaching $1.21. 30,550 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $1.20 and its 200 day moving average price is $1.19. The company’s market cap is $145.03 million. ImmunoVaccine has a 12 month low of $0.51 and a 12 month high of $1.70.
COPYRIGHT VIOLATION WARNING: “ImmunoVaccine Inc. (TSE:IMV) PT Set at C$2.50 by National Bank Financial” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/09/immunovaccine-inc-tseimv-pt-set-at-c2-50-by-national-bank-financial.html.
In other news, insider Pierre Labbé purchased 26,825 shares of the business’s stock in a transaction on Friday, July 28th. The stock was acquired at an average cost of C$1.22 per share, for a total transaction of C$32,726.50.
ImmunoVaccine Company Profile
Immunovaccine Inc is a Canada-based clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company’s DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications.
Receive News & Ratings for ImmunoVaccine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
